3.8 Article

Management and treatment outcomes of patients enrolled in MDR-TB treatment in Viet Nam

期刊

PUBLIC HEALTH ACTION
卷 6, 期 1, 页码 25-31

出版社

INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)
DOI: 10.5588/pha.15.0068

关键词

operational research; SORT IT; MDR-TB; programmatic management

资金

  1. Management Sciences for Health (Arlington, VA, USA)
  2. United States Agency for International Development (Washington, DC, USA)
  3. KNCV Tuberculosis Foundation (The Hague, The Netherlands)
  4. Global Fund (Geneva, Switzerland)
  5. Bloomberg Philanthropies, New York, NY, USA
  6. Union
  7. MSF
  8. Department for International Development, London, UK
  9. WHO, Geneva, Switzerland
  10. Fondation Veuve Emile Metz-Tesch, Luxembourg
  11. WHO

向作者/读者索取更多资源

Setting: The programmatic management of drug-resistant tuberculosis (TB) in Viet Nam has been rapidly scaled up since 2009. Objectives: To document the annual numbers of patients enrolled for multidrug-resistant tuberculosis (MDR-TB) treatment during 2010-2014 and to determine characteristics and treatment outcomes of patients initiating treatment during 2010-2012. Design: A retrospective cohort study using national reports and data from the national electronic data system for drug-resistant TB. Results: The number of patients enrolled annually for MDR-TB treatment increased from 97 in 2010 to 1522 in 2014. The majority of patients were middle-aged men who had pulmonary disease and had failed a retreatment regimen; 77% had received. 2 courses of TB treatment. Favourable outcomes (cured and treatment completed) were attained in 73% of patients. Unfavourable outcomes included loss to follow-up (12.5%), death (8%) and failure (6.3%). Having had. 2 previous treatment courses and being human immunodeficiency virus-positive were associated with unfavourable outcomes. Conclusion: Increasing numbers of patients are being treated for MDR-TB each year with good treatment outcomes under national programme management in Viet Nam. However, there is a need to increase case detection-currently at 30% of the estimated 5100 MDR-TB cases per year, reduce adverse outcomes and improve monitoring and evaluation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

3.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据